Donoghue Forlines LLC Makes New Investment in Insulet Co. (NASDAQ:PODD)

Donoghue Forlines LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,812 shares of the medical instruments supplier’s stock, valued at approximately $2,039,000.

Several other institutional investors have also recently modified their holdings of PODD. Integrated Wealth Concepts LLC boosted its position in Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 42 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after acquiring an additional 43 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 47 shares during the period. Graypoint LLC increased its stake in shares of Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after acquiring an additional 47 shares during the period. Finally, Wedmont Private Capital lifted its position in Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 48 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Wells Fargo & Company lifted their target price on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Morgan Stanley increased their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Trading Up 0.9 %

PODD opened at $278.65 on Thursday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $19.54 billion, a P/E ratio of 47.71, a P/E/G ratio of 3.47 and a beta of 1.22. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $282.86. The business has a fifty day simple moving average of $266.52 and a 200-day simple moving average of $234.38.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. During the same quarter in the prior year, the company earned $0.71 earnings per share. On average, equities analysts expect that Insulet Co. will post 3.22 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.